Company Profile
Fate Therapeutics Stock Price, News & Analysis
- Ticker:
- FATE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.49 USD (-4.23%)
Close
Last updated: August 6, 2026
300M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, FATE closed down 4.23% at $2.49. No new same-company headline was identified in the current news window.
Company overview
iPSC-Derived Cell Therapy Platform
Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.
FT819
FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell collection.
Lupus Development
Clinical work includes systemic lupus erythematosus and lupus nephritis, using reduced conditioning to improve treatment accessibility.
Broader Pipeline
FT839 is an earlier program designed for broad targeting of hematologic malignancies and autoimmune disease without conventional conditioning chemotherapy.
Future catalysts
The potentially registrational Phase 2 RECLAIM-LN study of FT819 in refractory lupus nephritis is scheduled to begin in the second half of 2026.
Recent news
- 01
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Source: Fate Therapeutics
- 02
- 03
- 04
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Source: Fate Therapeutics
- 05
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Source: Fate Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Fate Therapeutics (FATE)?
Fate Therapeutics (FATE) most recently closed at 2.49 USD, a -4.23% move versus the previous session.
What is the market cap of Fate Therapeutics (FATE)?
Fate Therapeutics currently has a market capitalization of 300M USD on BioPharmSignal.
What does Fate Therapeutics do?
iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells. FT819 FT819 is an iPSC-derived CD19 CAR T-cell therapy for autoimmune disease. The platform is intended to provide standardized manufacturing and repeatable dosing without patient-specific cell...
On which exchange is FATE stock listed?
Fate Therapeutics (FATE) is associated with NASDAQ, United States, Biopharma.
What is RECLAIM-LN?
The potentially registrational Phase 2 RECLAIM-LN study of FT819 in refractory lupus nephritis is scheduled to begin in the second half of 2026.
Which conditions is Fate Therapeutics targeting with RECLAIM-LN?
The potentially registrational Phase 2 RECLAIM-LN study of FT819 in refractory lupus nephritis is scheduled to begin in the second half of 2026.
How does Fate Therapeutics describe recent progress with RECLAIM-LN?
The potentially registrational Phase 2 RECLAIM-LN study of FT819 in refractory lupus nephritis is scheduled to begin in the second half of 2026.
What is Derived?
iPSC-Derived Cell Therapy Platform Fate Therapeutics develops off-the-shelf cellular immunotherapies manufactured from induced pluripotent stem cells.